In this issue:
Carboplatin + nab-paclitaxel vs. docetaxel in elderly squamous NSCLC
Atezolizumab, nivolumab and docetaxel in previously treated NSCLC
Immunotherapy for metastatic NSCLC
Carboplatin + pemetrexed then maintenance pemetrexed in elderly advanced nonsquamous NSCLC
First-line niraparib + pembrolizumab in advanced NSCLC
First-line osimertinib for advanced EGFR-positive NSCLC in the real world
First-line osimertinib for EGFR-mutant NSCLC with low Thr790Met allelic fraction
Smoking history for predicting response to ICIs in metastatic NSCLC
Therapeutic strategies for osimertinib resistance by EGFR T790M-cis-C797S in lung adenocarcinoma
Lung cancer resection for NSCLC after ICI therapy
Please login below to download this issue (PDF)